Reply to: Safety of dopamine agonists for treating restless legs syndrome.

Autor: Salminen AV; Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany., Allen RP; Sleep Disorders Center, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States.; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States., Högl B; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Inoue Y; Japan Somnology Center, Neuropsychiatric Research Institute, Tokyo, Japan.; Department of Somnology, Tokyo Medical University, Tokyo, Japan., Oertel W; Department of Neurology, Philipps-Universität Marburg, Marburg, Germany., Winkelman JW; Harvard Medical School, Boston, Massachusetts, United States.; Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States., Trenkwalder C; Department Neurosurgery, University Medical Center, Goettingen, Germany.; Paracelsus-Elena Hospital, Kassel, Germany., Sampaio C; CHDI Foundation, Princeton, New Jersey, USA., Winkelmann J; Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.; Chair Neurogenetics and Institute of Human Genetics, Technical University Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Jazyk: angličtina
Zdroj: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2019 Jan; Vol. 34 (1), pp. 150-151.
DOI: 10.1002/mds.27571
Databáze: MEDLINE